Return to Faculty List

Faculty

David R. Taft

Professor of Pharmaceutics, Full-time

B.S. (Pharmacy), University of Rhode IslandPh.D., University of Connecticut

Description

David R. Taft is Professor of Pharmaceutics of the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University (LIU Pharmacy). He received his undergraduate degree in Pharmacy from the University of Rhode Island and his Ph.D. in Pharmaceutical Science from the University of Connecticut. He joined the faculty of Long Island University after completing a post-doctoral fellowship at the University of North Carolina School of Pharmacy.

Professor Taft has served on the faculty of LIU Pharmacy for over two decades. His research interests are in the area of pharmacokinetics with a focus on drug disposition mechanisms, and he has collaborated with numerous pharmaceutical companies on preclinical evaluation of novel therapeutic entities. He has published more than 100 manuscripts, research abstracts and book chapters, and he co-edited two books. He serves on the editorial advisory boards of Journal of Pharmaceutical Sciences and Drug Development and Industrial Pharmacy. Dr. Taft is a past recipient of the American Association of Pharmaceutical Scientists (AAPS) New Investigator Grant in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, and the University of Connecticut School of Pharmacy Distinguished Alumnus Award.

Specialties

  • Pharmacokinetic evaluation of novel anticancer compounds
  • Pharmaceutical formulation development and evaluation
  • Pharmacokinetic modeling and simulation
  • Preclinical drug disposition studies – in vitro and in vivo

Publications


  • Suvarchala Kiranmai Avvari, Jaclyn A. Cusumano ,Vamshi Krishna Jogiraju, Pooja Manchandani, and David R. Taft. PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population. Pharmaceutics 15:2520 2023 https://doi.org/10.3390/pharmaceutics15112520.
  • Harsh Shah, Kushal Shah, Bhavin Gajera, Rutesh H. Dave, and David R. Taft. Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole. Pharmaceutics 15(4):1040 2023. doi:10.3390/pharmaceutics15041040.
  • Harshith Neeli, Nazeeh Hanna, Khaled Abduljalil, Jaclyn Cusumano, and David R. Taft. Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect. Journal of Clinical Pharmacology 61:1356-1365, 2021. doi: 10.1002/jcph.1890. Epub June 8, 2021. PMID: 33945155
  • Vamshi Krishna Jogiraju, Tycho Heimbach, Yuliana Toderika, and David R. Taft. Physiologically Based Pharmacokinetic Modeling of Altered Tizanidine Systemic Exposure by CYP1A2 Modulation: Impact of Drug-Drug Interactions and Cigarette Consumption. Drug Metabolism and Pharmacokinetics 37:100375, 2021 doi: 10.1016/j.dmpk.2020.100375. Epub 2020 Dec 13.
  • Kushal Shah, Briann Fischetti, Agnes Cha, and David R. Taft. Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients with Renal Impairment: An Example with Lamivudine. Current Drug Discovery Technologies 17:387-396, 2020. doi: 10.2174/1570163816666190214164916.
  • Jennypher Mudunuru, Chen Ren, David R. Taft, and Manoj Maniar. Effect of Gender on the Pharmacokinetics of ON 123300, a Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats. European Journal of Drug Metabolism and Pharmacokinetics. 44:531-538, 2019. doi: 10.1007/s13318-019-00542-2.
  • Briann Fischetti, Kushal Shah, David R. Taft, Leonard Berkowitz, Anjali Bakshi, and Agnes Cha. Real-World Experience with Higher-Than-Recommended Doses of Lamivudine in Patients with Varying Degrees of Renal Impairment. Open Forum Infectious Diseases, ofy225, doi:10.1093/ofid/ofy225, eCollection October 2018.
  • Vamshi Krishna Jogiraju, Suvarchala Avvari, Rakesh Gollen, and David R. Taft. Application of Physiologically-Based Pharmacokinetic Modeling to Predict Drug Disposition in Pregnant Populations. Biopharmaceutics and Drug Disposition 38: 426- 438, 2017.
  • Vidhiben Shah, Robert A. Bellantone, and David R. Taft. Evaluating the Potential for Delivery of Irinotecan via the Buccal Route: Physicochemical Characterization and In Vitro Permeation Assessment Across Porcine Buccal Mucosa. AAPS PharmSciTech. 18:867-874, 2017.
  • Aruna Dontabhaktuni, David R. Taft, and Mayankbhai Patel. Gentamicin Renal Excretion in Rats: Probing Strategies to Mitigate Drug-Induced Nephrotoxicity. Pharmacology & Pharmacy 7:43-55,2016.
  • Rami S. Komrokji, Azra Raza, Jeffrey E. Lancet, Chen Ren, David Taft, Manoj Maniar, Francois Wilhelm and Alan F. List. Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndrome. British Journal of Haematology 162:517-254, 2013.
  • Takao Ohnuma, Deborah Lehrer, Chen Ren, Sool Yeon Cho, Manoj Maniar, Lewis Silverman, Max Sung1 Herbert F Gretz III, Vladimir Benisovich, Shyamala Navada, Eugene Akahoho, Eric Wilck, David R. Taft, John Roboz, Francois Wilhelm, and James F Holland. Phase 1 Study of Intravenous Rigosertib (ON 01910.Na), a Novel Benzyl Styryl Sulfone Structure Producing G2/M Arrest and Apoptosis, in Adult Patients with Advanced Cancer. American Journal of Cancer Research 3:323-338, 2013.
  • Michael P. White, Mariana Babayeva, David R. Taft, and Manoj Maniar. Determination of Intestinal Permeability of Rigosertib (ON 01910.Na, Estybon™): Correlation with Systemic Exposure. Journal of Pharmacy and Pharmacology 65:960-969, 2013.
  • Mitalee Tamhane, Manoj Maniar, Chen Ren, Kenza E. Benzeroual and David R. Taft. Disposition of ON 01210.Na (Ex-RAD®), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure. Journal of Pharmaceutical Sciences 102:732–740, 2013.
  • Shubhankar Suman, Kamal Datta, Kathryn Doironi, Chen Ren, Ramesh Kumar, David R. Taft, Albert J. Fornace Jr., and Manoj Maniar. Radioprotective Effects of ON 01210.Na upon Oral Administration. Journal of Radiation Research 53:368-376, 2012.
  • Horatio Priestap, Maria Torres, Robert Rieger, Kathleen Dickman, Tomoko Freshwater, David R. Taft, Manuel Barbieri and Charles Iden. Aristolochic Acid I Metabolism in the Isolated Perfused Rat Kidney. Chemical Research in Toxicology 25:130-139, 2012.
  • Mariana Babayeva, Susan Cox, Michael P. White, and David R. Taft. Renal Excretion of Apricitabine in Rats: Ex Vivo and In Vivo Studies. European Journal of Drug Metabolism and Pharmacokinetics 36(3):141-150, 2011.
  • David R. Taft, Rutesh Dave, Amanda M. Gillum and Manoj Maniar. ON 01910.Na (Estybon®, Rigosertib). Drugs of the Future, 36(6):433-440, 2011.
  • Amy W. Chun, Robert E. Freshwater, David R. Taft, Amanda M. Gillum and Manoj Maniar. The Effect of Formulation and Route of Administration on the Systemic Availability of Ex-RAD, a New Radioprotectant, in Preclinical Species. Biopharmaceutics and Drug Disposition 32(2):99-111, 2011.
  • Antoinette Ajavon, Peter Bonate, and David R. Taft. Renal Excretion of Clofarabine: Assessment of Dose-linearity and Role of Renal Transport Systems on Drug Excretion. European Journal of Pharmaceutical Sciences 40(3):209-216, 2010.
  • Mitalee Tamhane, Ananthsrinivas R. Chakilam, Andrew Jayaraj, Vineet Thakkar, and David R. Taft. Comparative Renal Excretion of VX-702, a Novel P38 Mapk Inhibitor, and Methotrexate in the Perfused Rat Kidney Model. Drug Development and Industrial Pharmacy 36(3):315-322, 2010.
  • Amy W. Chun, Stephen C. Cosenza, David R. Taft and Manoj Maniar. Preclinical Pharmacokinetics and In Vitro Activity of ON 01910.Na, a Novel Anti-cancer Agent. Cancer Chemotherapy and Pharmacology 65(1):177-86, 2009.
  • Tomoko Nakatani-Freshwater and David R. Taft. Renal Excretion of Emtricitabine II. Effect of Trimethoprim on Emtricitabine Excretion: In Vitro and In Vivo Studies. Journal of Pharmaceutical Sciences 97(12):5411-5420, 2008.
  • Tomoko Nakatani-Freshwater and David R. Taft. Renal Excretion of Emtricitabine I. Effects of Organic Anion, Organic Cation, and Nucleoside Transport Inhibitors on Emtricitabine Excretion. Journal of Pharmaceutical Sciences 97(12):5401-5410, 2008.
  • David R. Taft, Ishani A. Savant, Aruna Dontabhaktuni, Mariana Babayeva and Tomoko Nakatani-Freshwater. Application of the Isolated Perfused Rat Kidney Model to Assess Gender Effects on Drug Excretion. Drug Development and Industrial Pharmacy 32(8):919-28, 2006.
  • Tomoko Nakatani-Freshwater, Mariana Babayeva, Aruna Dontabhaktuni, and David R. Taft. Effects of Trimethoprim on the Clearance of Apricitabine, a Deoxycytidine Analog Reverse Transcriptase Inhibitor, and Lamivudine in the Isolated Perfused Rat Kidney. Journal of Pharmacology and Experimental Therapeutics 319(2):941-947, 2006.
  • Madiha B. Sidhom, Nadya Rivera, Hassan Almoazen, Harold L. Kirschenbaum, and David R. Taft. Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations. International Journal of Pharmaceutical Compounding 9(5):402-406, 2005.
  • Roda Plakogiannis, Henry Cohen, and David Taft. Effects of Morning Versus Evening Administration of Atorvastatin in Patients with Hyperlipidemia. American Journal of Health Systems Pharmacy 62(23):2491-2494, 2005.
  • Mohammed A. Kabir, David R. Taft, Cecil K. Joseph, and Robert A Bellantone. Measuring Drug Concentrations Using Pulsatile Microdialysis: Theory and Method Development In Vitro. International Journal of Pharmaceutics, 293:171-182, 2005.
  • David R. Taft. The Isolated Perfused Rat Kidney Model: A Useful Tool for Drug Discovery and Development. Current Drug Discovery Technologies 1:97-111, 2004.
  • Nagaraju R. Poola, Michelle Kalis, Fotios Plakogiannis, and David R. Taft. Characterization of Pentamidine Excretion in the Isolated Perfused Rat Kidney. Journal of Antimicrobial Chemotherapy 52(3):397-404, 2003.
  • Mohammed Nasser Ali Christy, Robert A. Bellantone, David R. Taft and Fotios .M. Plakogiannis. In Vitro Evaluation of the Release of Albuterol Sulfate from Polymer Gels: Effect of Fatty Acids on Drug Transport Across Biological Membranes. Drug Development and Industrial Pharmacy 28:1221-1229, 2002.
  • Nagaraju R. Poola, Dider Bhuiyan, Michelle Kalis, Stephan Ortiz, Ishani A. Savant, Harold Kirschenbaum, Madiha Sidhom and David R. Taft. A Novel HPLC Assay for Pentamidine: Comparative Effects of Creatinine and Inulin on GFR Estimation and Pentamidine Renal Excretion in the Isolated Perfused Rat Kidney. Journal of Pharmacy and Pharmaceutical Sciences 5(2):130-140, 2002.
  • Malaz A. AbuTarif and David R. Taft. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Carbonic Anhydrase Binding on Drug Disposition. Pharmaceutical Research 19:551-555, 2002.
  • Ishani A. Savant, Michelle Kalis, Hassan Almoazen, Stephan R. Ortiz, Malaz AbuTarif and David R. Taft. Alternative High-Performance Liquid Chromatographic Assay for p- Aminohippuric Acid (PAH): Effect of Aging on PAH Excretion in the Isolated Perfused Rat Kidney. Journal of Pharmaceutical and Biomedical Analysis 26:687-699, 2001.
  • Ganesh R. Iyer, Robert A. Bellantone and David R. Taft. In Vitro Characterization of the Erythrocyte Distribution of Methazolamide: A Model of Erythrocyte Transport and Binding Kinetics. Journal of Pharmacokinetics and Biopharmaceutics 27,45-66, 1999.
  • David R. Taft, Sean Nordt, Ganesh R. Iyer, and Michael H. Schwenk. Blood Disposition and Urinary Excretion Kinetics of Methazolamide Following Oral Administration to Human Subjects. Biopharmaceutics and Drug Disposition 19(6):373-380, 1998.
  • David R. Taft. One-Compartment Model with Zero-Order Input: The Constant Rate Intravenous Infusion. American Journal of Pharmaceutical Education 62(2):170-176, 1998.
  • Ganesh R. Iyer and David R. Taft. Determination of Methazolamide Concentrations in Human Biological Fluids by High Performance Liquid Chromatography. Journal of Pharmaceutical and Biomedical Analysis 16(6):1019-1024, 1998.
  • David R. Taft, Ganesh R. Iyer, Leon Behar and Robert V. DiGregorio. Application of a First-Pass Effect Model to Characterize the Pharmacokinetic Disposition of Venlafaxine Following Oral Administration to Human Subjects. Drug Metabolism and Disposition 25:1215-1218, 1997.
  • Christopher J. Matheny, David R. Taft, Kim L.R. Brouwer and Gary M. Pollack. Evidence for Reversible Sequestration of Morphine in Rat Liver. Biochemical Pharmacology 52:535-541, 1996.
  • David R. Taft, Donna J. Fournier, Dennis J. Chapron and Kevin R. Sweeney. Concentration Dependent Tubular Secretion of Acetazolamide and its Inhibition by Salicylic Acid in the Isolated Perfused Rat Kidney. Drug Metabolism and Disposition 24(4):456-451, 1996.
  • Kevin R. Sweeney, Poe-Hirr Hsyu, Paul Statkevich, and David R. Taft. Renal Disposition and Drug Interaction Screening of (-)-2/-Deoxy-3/-Thiacytidine (3TC) in the Isolated Perfused Rat Kidney. Pharmaceutical Research 12(12):1958-1963, 1995.
  • David R. Taft and Kevin R. Sweeney. The Influence of Protein Binding on the Elimination of Acetazolamide by the Isolated Perfused Rat Kidney: Evidence of Albumin-Mediated Tubular Secretion. Journal of Pharmacology and Experimental Therapeutics 274:752-760, 1995.

Books

  • Mark C. Rogge and David R. Taft (Eds), Preclinical Drug Development, Second Edition, New York, Informa Healthcare, 2009.
  • Robert O. Williams III, David R. Taft and Jason T. McConville (Eds), Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, New York, Informa Healthcare, 2007.
  • Mark C. Rogge and David R. Taft (Eds), Preclinical Drug Development, New York, Informa Healthcare, 2005.

Book Chapters

  • David R. Taft. Drug Excretion. In: Miles Hacker, Kenneth Bachmann, and William Messer (Eds). Pharmacology: Principles and Practice, Amsterdam, Academic Press, 2009.
  • Antoinette D. Ajavon and David R. Taft. Pharmacokinetics/ADME of Small Molecules. In: Mark C. Rogge and David R. Taft (Eds) Preclinical Drug Development, 2nd Edition, New York, Informa Healthcare, 2009.
  • Xudong Yuan and David Taft. Advanced Formulation Strategies for Central Nervous System Drug Delivery. In: Robert O Williams, David R. Taft, and Jason T. McConville (Eds). Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, New York, Informa Healthcare, 2007.
  • David Taft and Xudong Yuan. Advanced Formulation Strategies for Anti-Cancer Drug Delivery. In: Robert O Williams, David R. Taft, and Jason T. McConville (Eds). Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, New York, Informa Healthcare, 2007.
  • Kevin R. Sweeney and David R. Taft. Assessment of Pharmacokinetics and Drug Activity: Isolated Organ Systems and the Membrane Transporter Family. In: Mark C. Rogge and David R. Taft (Eds) Preclinical Drug Development, New York, Informa Healthcare, 2005.
  • Malaz AbuTarif, Ganesh R. Iyer, Vidya Sankaragarayanan, Robert A. Bellantone and David R. Taft. Erythrocyte Distribution Kinetics of the Carbonic Anhydrase Inhibitor Methazolamide: Application of In Vitro Studies to Predict In Vivo Drug Disposition. In: SG Pandalai (Ed) Recent Developments in Drug Metabolism Vol 1, pp:117-131, 2002.

Lectures and Presentations

  • R. Gollen and D.R. Taft, “Application of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation to Predict Systemic Drug Exposure During Pregnancy”, 2014 AAPS Annual Meeting and Exposition; San Diego, CA., 2014
  • V. M. Shah, D. Taft, and M. Maniar, “Determination of Physicochemical Properties of Irinotecan (CPT-11), an Anticancer Drug”, 2013 AAPS Annual Meeting and Exposition; November; San Antonio, TX, 2013
  • M. Babayeva, J. Tang, A. Ajavon, and D. Taft, “Excretion Profile of Aristolochic Acid I in the Isolated Perfused Rat Kidney”, 2013 AAPS Annual Meeting and Exposition; November; San Antonio, TX, 2013
  • K. J. Burns, D.R. Taft, C. Ren, K. E. Benzeroual, and M. Maniar, “Hepatobiliary Disposition of Rigosertib (ON 01910.Na, EstybonTM) in the Isolated Perfused Rat Liver following Chronic Oral Dosing to Wild-Type and Mdr1a-/- Knockout Rats”, 2013 AAPS Annual Meeting and Exposition; November; San Antonio, TX, 2013
  • X. Wang, V.M. Shah, R. Bellantone, D. Taft, and M. Maniar, “In Vitro Permeation of ON 01210.Na (Ex–RADÔ) through Porcine Skin.”, 2012 AAPS Annual Meeting and Exposition; Chicago, IL, 2012
  • Y. Patel and D.R. Taft., “Uricosuric Effect of Benzbromarone in the Isolated Perfused Rat Kidney Model”, 2012 AAPS Annual Meeting and Exposition; Chicago, IL, 2012
  • H.H. Patel, C. Ren, M. Maniar, D. Taft, and R.H. Dave., “Determination of Degradation Kinetics of EstybonÔ—A Novel Anticancer Drug in Acidic Conditions”, 2012 AAPS Annual Meeting and Exposition; Chicago, IL, 2012
  • A. Patel, R. Gollen, D.R. Taft, and M. Babayeva, “Gender Differences in Renal Excretion of Metformin in Rats”, 2012 AAPS Annual Meeting and Exposition; Chicago, IL, 2012
  • A. Raza, R.S. Komrokji, R. Brooks, J.E. Lancet, A.F. List, C. Ren, D.R. Taft, F. Wilhelm, and M. Maniar., “A Phase I Study to Assess Oral Bioavailability of a Novel Oral Soft Gelatin Capsule Formulation of Rigosertib (ON 01910.Na) Under Fasted and Fed Conditions in Patients with Myelodysplastic Syndromes.”, Journal of Clinical Oncology 30, 2012 (suppl; abstr 3081)
  • M. White, D. Taft, M. Maniar, and M. Babayeva., “Determination of Intestinal Permeability of ON 01910.Na, a Novel Anti-Cancer Agent, in the In Situ Perfused Rat Intestine”,The AAPS Journal 13(S2), Abstract 2352, 2011.
  • A. Patel, D. Taft, and M. Babayeva., “Gender Differences in Renal Excretion of Trimethoprim.”, The AAPS Journal 13(S2), Abstract 6385, 2011.
  • C. Ren, M. Tamhane, D. Taft, and M. Maniar, “Effect of Ethacrynic Acid (EA) on the Pharmacokinetics of Ex-RAD® (ON 01210.Na) in the Isolated Perfused Rat Liver Model (IPRLM)”, 4th International Congress of Radiation Research, Warsaw, Poland, 2011

Grants/Contracts

  • U.S. Food and Drug Administration, Grant 1U01FD006930, “Elucidating Fundamental Principles of Dermal Pharmacokinetics via Microdialysis”, PI (Taft), $217,946, 7/1/2022- 6/30/2023
  • Certara-Simcyp Grant and Partnership Scheme, "Utilization of Physiologically-Based Pharmacokinetic Modeling to Predict Drug Disposition and Guide Dosing Decisions in Preterm Neonates", $59,700, 2018-2020
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $48,954, 2015.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $49,231, 2014.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $35,585, 2013.
  • TPP Global Development, “Preclinical Studies with Novel Compounds”, $9,000, 2013. Parion Sciences, Inc, “Renal Excretion of Parion ENaC blockers in the Isolated Perfused Rat Kidney”, $25,684, 2011.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $37,386, 2010.
  • Ardea Biosciences, “Preclinical Studies with Novel Therapeutic Compounds”, $9,000, 2010. Parion Sciences, Inc, “Renal Excretion of Parion ENaC blockers in the Isolated Perfused Rat Kidney”, $52,764, 2009.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $51,264, 2009.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $71,936, 2008.
  • Genzyme Oncology Inc, “Pharmacokinetic Studies with Clofarabine and Other Nucleoside Analogs: In Vivo and Isolated Perfused Kidney Studies”, $70,000, 2007.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $68,550, 2007.
  • Genzyme Oncology Inc, “Renal Excretion of Clofarabine in the Isolated Perfused Rat Kidney: Assessment of Dose Linearity and Role of Renal Transport Systems on Drug Excretion”, $44,000, 2007.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $68,894, 2006.
  • Vertex Pharmaceuticals Inc, “Renal Excretion of a Novel Compound in the Isolated Perfused Rat Kidney: Assessing Potential Interaction with Methotrexate”, $18,000, 2006.
  • Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $60,000, 2005.
  • Shire Pharmaceutical Development, “Assessment of Dose Linearity of the Renal Clearance of SPD-754 and its Metabolite BCH335 in the Isolated Perfused Rat Kidney”, $29,975, 2004.
  • Shire Pharmaceutical Development, “Effect of Potential Interactants on the Renal Disposition of SPD-754 and BCH-355 in the Isolated Perfused Rat Kidney”, $24,706, 2004.
  • Shire Pharmaceutical Development, “Effect of Trimethoprim on the Renal Disposition of BCH-335 in the Isolated Perfused Rat Kidney”, $21,670, 2003.
  • Shire Pharmaceutical Development, “Effect of Trimethoprim on the Renal Disposition of SPD-754 and 3TC in the Isolated Perfused Rat Kidney”, $42,600, 2003. 1996-1997 New Investigators Program Grant, American Association of Colleges of Pharmacy, "Investigation of a Facilitative Role of Albumin in Renal Clearance", $10,000.

Honors/Awards

  • COVID-19 Outstanding Faculty Recognition Award, Arnold & Marie Schwartz College of Pharmacy, Long Island University, 2021
  • Certara Simcyp Academic Award, Most Effective Teaching Application, Long Island University, 2016
  • University of Connecticut School of Pharmacy Distinguished Alumnus Award, 2011 American Association of Colleges of Pharmacy Academic Leadership Fellow, 2004-2005 Founders Award for Faculty, Arnold & Marie Schwartz College of Pharmacy, Long Island
  • University, 2002
  • American Association of Pharmaceutical Scientists New Investigator Grant Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, 1998
  • David Newton Award for Excellence in Teaching, Long Island University, 1997 American Foundation for Pharmaceutical Education (AFPE) Fellow, 1989-1992

Professional Affiliations

  • American College of Clinical Pharmacology 
  • American Association of Pharmaceutical Scientists
  • Phi Lambda Sigma Pharmacy Leadership Society
  • Rho Chi Pharmacy Honor Society

Editorial Board Appointment

  • AAPS Introductions in the Pharmaceutical Sciences (2021-present) 
  • Current Drug Discovery Technologies (2007-present)

Editorial Advisory Board Appointments

  • Journal of Pharmaceutical Sciences (2003 – present)
  • Drug Development and Industrial Pharmacy (2005- present)